Terms: = Endocrine gland cancer AND LPP, Q93052, 4026, ENSG00000145012
12 results:
1. LINC00092 Enhances lpp Expression to Repress Thyroid cancer Development via Sponging miR-542-3p.
Wang H
Horm Metab Res; 2024 Feb; 56(2):150-158. PubMed ID: 37935247
[TBL] [Abstract] [Full Text] [Related]
2. Long Non-Coding RNA lpp-AS2 Plays an Anti-Tumor Role in Thyroid Carcinoma by Regulating the miR-132-3p/OLFM1 Axis.
Zhang B; Liu T; Gu Y; Ren L; Wang J; Feng C; Song Z
Crit Rev Eukaryot Gene Expr; 2023; 33(5):73-86. PubMed ID: 37199315
[TBL] [Abstract] [Full Text] [Related]
3. Case Report: Identification of Potential Prognosis-Related
Zhang Y; Ma L; Liu J; Zhu H; Lu L; Deng K; Ma W; Pan H; Wang R; Yao Y
Front Endocrinol (Lausanne); 2021; 12():673908. PubMed ID: 34381423
[TBL] [Abstract] [Full Text] [Related]
4. Value of a genetics clinic evaluation in identifying women at risk for hereditary breast-ovarian cancer syndrome.
Hinshaw JC; Zhao LP; Brimm JE; Payne TH; Hisama FM
J Genet Couns; 2021 Dec; 30(6):1591-1597. PubMed ID: 33881185
[TBL] [Abstract] [Full Text] [Related]
5. Expression of lipoma preferred partner in mammary and extramammary Paget disease.
Liu Y; Wang Y; Qi R; Mao X; Jin F
Medicine (Baltimore); 2020 Dec; 99(51):e23443. PubMed ID: 33371071
[TBL] [Abstract] [Full Text] [Related]
6. Distinct Clinical Courses of Epithelial Ovarian cancer with Mutations in
Eoh KJ; Park HS; Park JS; Lee ST; Han JW; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
Anticancer Res; 2018 Dec; 38(12):6947-6953. PubMed ID: 30504414
[TBL] [Abstract] [Full Text] [Related]
7. cancer-associated fibroblasts regulate endothelial adhesion protein lpp to promote ovarian cancer chemoresistance.
Leung CS; Yeung TL; Yip KP; Wong KK; Ho SY; Mangala LS; Sood AK; Lopez-Berestein G; Sheng J; Wong ST; Birrer MJ; Mok SC
J Clin Invest; 2018 Feb; 128(2):589-606. PubMed ID: 29251630
[TBL] [Abstract] [Full Text] [Related]
8. Phase 1 trials in pancreatic cancer.
Yu E; Saif MW; Huber K
JOP; 2014 Jul; 15(4):326-8. PubMed ID: 25076334
[TBL] [Abstract] [Full Text] [Related]
9. [Lysophosphatidic acid as a potential target for treatment and molecular diagnosis of epithelial ovarian cancers].
Tanyi J; Rigó J
Orv Hetil; 2009 Jun; 150(24):1109-18. PubMed ID: 19739275
[TBL] [Abstract] [Full Text] [Related]
10. Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer.
Tanyi JL; Hasegawa Y; Lapushin R; Morris AJ; Wolf JK; Berchuck A; Lu K; Smith DI; Kalli K; Hartmann LC; McCune K; Fishman D; Broaddus R; Cheng KW; Atkinson EN; Yamal JM; Bast RC; Felix EA; Newman RA; Mills GB
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3534-45. PubMed ID: 14506139
[TBL] [Abstract] [Full Text] [Related]
11. The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer.
Tanyi JL; Morris AJ; Wolf JK; Fang X; Hasegawa Y; Lapushin R; Auersperg N; Sigal YJ; Newman RA; Felix EA; Atkinson EN; Mills GB
Cancer Res; 2003 Mar; 63(5):1073-82. PubMed ID: 12615725
[TBL] [Abstract] [Full Text] [Related]
12. Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells.
Chung I; Schwartz PE; Crystal RG; Pizzorno G; Leavitt J; Deisseroth AB
Cancer Gene Ther; 1999; 6(2):99-106. PubMed ID: 10195877
[TBL] [Abstract] [Full Text] [Related]
